Stock Price & Analysis

-
$
0.000
0.000(0%)6M

TWST Stock Price Chart

5D
1M
3M
6M
YTD
1Y
5Y

TWST Fundamental Analysis

5
buy
Moderate Buy
Buy
Hold
Sell
bubble
High
62.00
bubble
Averages
54.29
bubble
Low
40.00
Analyst
Rating
Action
Price Target
Date
Rating Reason
Baird
Catherine Ramsey
Buy
Maintains
$48 → $54
2025-02-04
JP Morgan
Rachel Vatnsdal
Sell
Maintains
$35 → $40
2025-02-04
Scotiabank
Sung Ji Nam
Buy
Maintains
$54 → $62
2025-02-04
Wolfe Research
Doug Schenkel
Buy
Initiates
$60
2024-12-13
Wolfe
bubble
TD Cowen
Steven Mah
Strong Buy
Reiterates
$58
2024-11-26
Sees
bubble

TWST Earnings Analysis

Twist Bioscience Corporation Common Stock Corporation (TWST.O) Q4 2024 Earnings Conference Call

Positive

  • Record Revenue and Margin Growth: Twist delivered record quarterly revenue and margin growth, ending the year with a strong cash balance.

  • Performance Exceeds Guidance: We exceeded our guidance in every metric, including total revenue, gross margin, capital expenditure and ending cash balance.

  • Consistent Revenue Increase: We increased revenue for the seventh quarter in a row, reporting $84.7 million, an increase of 27% year-over-year and 4% sequentially.

  • Revenue Increase of 28%: For the year, we reported $330 million in revenue, an increase of 28% over fiscal 2023.

  • Quarterly Gross Margin Performance: Gross margin for the quarter came in ahead of our guidance at 45.1%.

Negative

  • Adjusted EBITDA Improvement: For fiscal 2024, adjusted EBITDA was a loss of approximately $93.5 million, an improvement of approximately $54 million versus $147.3 million for fiscal 2023.

  • Operating Cash Flow Comparison: Net cash used in operating activities was $64.1 million compared to $142.5 million for the equivalent 12-month period in 2023.

  • Operating Expenses Comparison: Operating expenses, excluding cost of revenues for fiscal 2024 were $354 million, including the impairment charge of $45 million in fiscal Q3, compared with $307 million in fiscal 2023.

  • Gross Margin Improvement Outlook: We expect to see continued improvement in gross margins sequentially throughout the year, but the timing of which is a bit uncertain on some of when they'll actually hit the P&L.

  • Adjusted EBITDA Loss Forecast: We expect adjusted EBITDA losses of approximately $60 million to $65 million for fiscal 2025, an improvement of approximately $30 million to $35 million versus fiscal 2024.

TWST News

bubble
5.0
03-11Newsfilter
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost
bubble
5.0
03-01Benzinga
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
bubble
5.0
02-15Benzinga
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday
bubble
4.5
02-11NASDAQ.COM
Notable Two Hundred Day Moving Average Cross - TWST
bubble
5.0
02-11Benzinga
Cathie Wood Dumps $16 Million Worth Of Palantir Stock After Record Highs

TWST FAQs

Should I buy or sell TWST Stock?

Analysis and Insights

To determine whether to buy or sell TWST stock, we analyze both technical and fundamental factors:

Technical Analysis:

TWST's stock price has been experiencing volatility, with a recent decline in price. The stock is currently trading near its lower Bollinger Band, suggesting potential oversold conditions. The MACD indicator shows a bearish signal, and the RSI is around 50, indicating a neutral position.

Fundamental Analysis:

Ark Invest's recent purchase of TWST shares in February 2025 indicates confidence, but their subsequent sale may signal profit-taking. Analyst sentiment is mixed, with Baird maintaining a Buy rating and JP Morgan advising to Sell. The stock's valuation metrics and recent price movements suggest uncertainty.

Analyst Sentiment:

Analysts are divided, with some expecting growth and others cautioning against potential declines. The mixed ratings reflect the stock's uncertain outlook.

Conclusion:

Given the mixed analyst sentiment, recent price decline, and bearish technical indicators, it may be prudent to hold or wait for further positive developments before deciding to buy.

What is price prediction 2025 for TWST Stock?

What is surpport and resistant level for TWST Stock?

What is the current price of TWST Stock?

What is the target price of TWST Stock?

What is the market cap of Twist Bioscience Corp?

Is Twist Bioscience Corp (TWST) overvalued?

What is Twist Bioscience Corp (TWST)'s business?

What is price prediction 2030 for TWST Stock?

How many employees does TWST have?

TWST Key Stats

High
43.570
Vol
1.32M
Low
40.500
Amount
56.28M
Open
41.860
VWAP
42.64
Mkt Cap
2.56B

TWST Company Profile

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.